Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Aptamer Solutions Ltd
Aptamer Solutions Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle
AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Drug Delivery
Aptamer Group signs material agreement with genetic medicines company
Optimer binders will be developed to support targeted genetic medicines to specific cell types
Manufacturing
Aptamer and Neuro-Bio collaborate on Alzheimer’s disease diagnostic
The novel Alzheimer’s disease biomarker was discovered and is currently being further validated by Neuro-Bio, led by neuroscientist Baroness Susan Greenfield
Manufacturing
Aptamer launches reagent solution for immunohistochemistry
The Optimer-Fc is an antibody alternative for use within existing workflows replacing the primary, detecting, antibody
Drug Delivery
Aptamer partners with BaseCare Therapeutics
BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based medicines
Manufacturing
Appointment of Interim Chief Commercial Officer, Aptamer Group
Derek joined the company in 2018 as Director of Global Sales
Drug Delivery
Aptamer Group's new deal supports novel therapies
Since the publication of the group’s full year results, the company has signed deals with a number of companies related to the development of Optimer solutions
Subscribe now